Related by context. Frequent words. (Click for all words.) 70 relapsed refractory 69 multiple myeloma MM 68 leukemia CLL 68 metastatic hormone refractory 68 HER2 positive metastatic breast 68 indolent NHL 67 follicular B 67 follicular non 66 relapsed refractory multiple myeloma 66 Epratuzumab 65 plus prednisone 65 lymphoma CTCL 65 forodesine 64 pertuzumab 64 relapsed multiple myeloma 64 mRCC 64 biologic therapy 64 metastatic castration resistant 64 heavily pretreated 63 cell chronic lymphocytic 63 EGFR expressing metastatic colorectal 63 DLBCL 63 R sorafenib tablets 63 metastatic renal cell carcinoma 63 registrational trial 63 FavId 63 advanced carcinoid 63 Ofatumumab 63 Amrubicin 63 cell malignancies 62 HGS ETR1 62 liposomal formulation 62 superficial bladder cancer 62 multi kinase inhibitor 62 chronic lymphocytic leukemia CLL 62 Fludara 62 EFAPROXYN 62 androgen independent 62 plus dexamethasone 62 HRPC 62 cutaneous T cell 62 acute promyelocytic leukemia APL 62 Relapsed 62 Rituximab 62 docetaxel chemotherapy 62 Jevtana 62 non Hodgkin lymphomas 62 tanespimycin 62 EOquin 61 neoadjuvant 61 KRAS wild 61 mucosal healing 61 relapsing multiple sclerosis 61 non squamous 61 gastrointestinal stromal tumors GIST 61 xenograft models 61 non Hodgkin Lymphoma 61 plus gemcitabine 61 refractory multiple myeloma 61 ofatumumab 61 neoadjuvant chemotherapy 61 IIa trial 61 TORISEL 61 allogeneic stem cell 61 HER2 negative 61 mTOR inhibitor 61 acute myelogenous leukemia AML 61 nilotinib 61 Lenalidomide 61 carboplatin paclitaxel 61 chlorambucil 61 elotuzumab 60 B CLL 60 Urocidin 60 Vandetanib 60 Acute Myeloid Leukemia AML 60 axitinib 60 nab paclitaxel 60 RECIST criteria 60 chemoradiotherapy 60 heavily pretreated patients 60 OncoVEX GM CSF 60 Traficet EN 60 Panzem R 60 KRN# 60 evaluable 60 phase IIb clinical 60 primary hypercholesterolemia 60 Response Evaluation Criteria 60 DOXIL 60 romidepsin 60 gastrointestinal stromal tumors 60 myelodysplastic syndrome MDS 60 Irinotecan 60 Cloretazine R VNP#M 59 luteinizing hormone releasing 59 goserelin 59 ponatinib 59 Phase Ib clinical 59 IV metastatic melanoma 59 complete remissions